Advanced Lung Adenocarcinoma with EGFR 19-del Mutation Transformed into SCC after EGFR-tyrosine Kinase inhibitors Treatment:A Case report  

作　　者：Xing-Zu Ji Zhong-Da Liu Yi-Ping Ye Quan Li Xiao-Jing Liu Min-Hua Zhou Yi Jin 

机构地区：[1]Department of Respiratory and Critical Care Medicine,Lishui Hospital of Traditional Chinese Medicine,Lishui 323000,Zhejiang Province,China [2]Traditional Chinese Medicine Oncology,Lishui Hospital of Traditional Chinese Medicine,Lishui 323000,Zhejiang Province,China [3]Department of Emergency Medicine,Lishui People's Hospital,Lishui 323000,Zhejiang Province,China

出　　处：《World Journal of Clinical Cases》2024年第20期4405-4411,共7页世界临床病例杂志

摘　　要：BACKGROUND Epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs)significantly improve the survival of patients with Epidermal growth factor receptor(EGFR)sensitive mutations in non-small cell lung cancer(NSCLC).CASE SUMMARY A 67-year-old female patient in advanced lung adenocarcinoma suffered from drug resistance after EGFR-TKIs treatment.Secondary pathological tissue biopsy confirmed squamous cell carcinoma(SCC)transformation.Patients inevitably encountered drug resistance issues after receiving EGFR-TKIs treatment for a certain period of time,while EGFR-TKIs can significantly improve the survival of patients with EGFR-sensitive mutations in NSCLC.Notably,EGFR-TKIs resistance includes primary and acquired.Pathological transformation is one of the mechanisms of acquired resistance in EGFR-TKIs,with SCC transformation being relatively rare.Our results provide more detailed results of the patient’s diagnosis and treatment process on SCC transformation after EGFR-TKIs treatment for lung adenocarcinoma.CONCLUSION Squamous cell carcinoma transformation is one of the acquired resistance mechanisms of EGFR-TKIs in advanced lung adenocarcinoma with EGFR mutations.

关 键 词：Lung adenocarcinoma Squamous cell carcinoma Pathological histological transformation Epidermal growth factor receptor tyrosine kinase inhibitors Drug resistance Case report 

分 类 号：R734.2[医药卫生—肿瘤]